Similarly, addition of deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, but not addition of placebo to standard therapy was recently shown to reduce serum levels of BAFF, CCL8, and CXCL10 in patients with active SLE in the phase II PAISLEY (NCT03252587) trial (36, 37). This evidence concerns the gene TYK2 and systemic lupus erythematosus.